GCP
JSPR icon

GSA Capital Partners’s Jasper Therapeutics JSPR Stock Holding History

GSA Capital Partners’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$225K Buy
534,697
+515,613
+2,702% +$386K 0.01% 1474
2026
Q1 		$17K Sell
19,084
-55,880
-75% -$77.6K ﹤0.01% 1647
2025
Q4 		$137K Buy
+74,964
New +$150K 0.01% 1491

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

GSA Capital Partners's JSPR Position: Q2 2026 in Review

GSA Capital Partners increased its Jasper Therapeutics (JSPR) stake by 2,702% in Q2 2026, buying an estimated $386K and bringing the position to 534,697 shares worth $225K. The position accounts for 0.01% of the portfolio, ranked #1474.

GSA Capital Partners first reported a position in JSPR in Q4 2025 and has held it in 3 quarters since. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

  • GSA Capital Partners held 534,697 shares of Jasper Therapeutics worth $225K as of Q2 2026.
  • GSA Capital Partners bought 515,613 Jasper Therapeutics shares in Q2 2026, an estimated $386K.
  • Jasper Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q2 2026, its #1474 holding.
  • GSA Capital Partners first reported a position in Jasper Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.